These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
669 related articles for article (PubMed ID: 19909378)
1. Update on gout and hyperuricemia. Baker JF; Schumacher HR Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378 [TBL] [Abstract][Full Text] [Related]
2. The current state of care in gout: Addressing the need for better understanding of an ancient disease. Zychowicz ME; Pope RS; Graser E J Am Acad Nurse Pract; 2010 Nov; 22 Suppl 1():623-36. PubMed ID: 21054636 [TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout. Ernst ME; Fravel MA Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996 [TBL] [Abstract][Full Text] [Related]
5. Febuxostat--treatment for hyperuricemia and gout? Moreland LW N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099 [No Abstract] [Full Text] [Related]
6. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265 [TBL] [Abstract][Full Text] [Related]
7. Febuxostat: a new treatment for hyperuricaemia in gout. Edwards NL Rheumatology (Oxford); 2009 May; 48 Suppl 2():ii15-ii19. PubMed ID: 19447778 [TBL] [Abstract][Full Text] [Related]
8. Hyperuricaemia and gout: state of the art and future perspectives. Dalbeth N; So A Ann Rheum Dis; 2010 Oct; 69(10):1738-43. PubMed ID: 20858623 [TBL] [Abstract][Full Text] [Related]
12. Emerging therapies in the long-term management of hyperuricaemia and gout. Stamp LK; O'Donnell JL; Chapman PT Intern Med J; 2007 Apr; 37(4):258-66. PubMed ID: 17388867 [TBL] [Abstract][Full Text] [Related]
13. [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES]. Schils R; Krzesinski JM Rev Med Liege; 2016 May; 71(5):262-8. PubMed ID: 27337847 [TBL] [Abstract][Full Text] [Related]
14. Urate-lowering therapy for gout: focus on febuxostat. Love BL; Barrons R; Veverka A; Snider KM Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048 [TBL] [Abstract][Full Text] [Related]
15. [Hyperuricemia. When and how to treat?]. Reuss-Borst MA Internist (Berl); 2016 Feb; 57(2):194-201. PubMed ID: 26791735 [TBL] [Abstract][Full Text] [Related]
16. Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587 [TBL] [Abstract][Full Text] [Related]
17. 2011 Recommendations for the diagnosis and management of gout and hyperuricemia. Hamburger M; Baraf HS; Adamson TC; Basile J; Bass L; Cole B; Doghramji PP; Guadagnoli GA; Hamburger F; Harford R; Lieberman JA; Mandel DR; Mandelbrot DA; McClain BP; Mizuno E; Morton AH; Mount DB; Pope RS; Rosenthal KG; Setoodeh K; Skosey JL; Edwards NL; Postgrad Med; 2011 Nov; 123(6 Suppl 1):3-36. PubMed ID: 22156509 [TBL] [Abstract][Full Text] [Related]
18. Gout: what primary care physicians want to know. Dore RK J Clin Rheumatol; 2008 Oct; 14(5 Suppl):S47-54. PubMed ID: 18830091 [TBL] [Abstract][Full Text] [Related]
19. Febuxostat for prevention of gout attacks. Pohar S; Murphy G Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189 [TBL] [Abstract][Full Text] [Related]